Diarrhea News and Research

Latest Diarrhea News and Research

2M Pakistanis affected by diseases related to widespread flooding in southern region

Two million Pakistanis have become ill from malaria, diarrhea, skin diseases or snake bites "since monsoon rains left the southern region under several feet of water, the country's disaster authority said Thursday," Agence France-Presse reports. "More than 350 people have been killed and over eight million people have been affected this year by floods that officials say are worse in parts of Sindh province than last year," the news agency reports.

23 Sep 2011

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

Astellas Pharma Europe Ltd. (APEL) and Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhoea (CDAD).

23 Sep 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen announced today that data from XGEVA (denosumab) and Vectibix (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.

23 Sep 2011

Vaccinating infants against rotavirus decreases health care use and treatment costs

Vaccinating infants against rotavirus has resulted in dramatic decreases in health care use and treatment costs for diarrhea-related illness in U.S. infants and young children, according to a new study by the Centers for Disease Control and Prevention. The study is published in the current issue of the New England Journal of Medicine.

22 Sep 2011

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

22 Sep 2011

Peptide receptor radiolabeled therapy shows promise against neuroendocrine tumors

According to new Dutch research featured in the September issue of The Journal of Nuclear Medicine, a peptide receptor radiolabeled therapy (PRRT), [177Lu-DOTA0,Tyr3]Octreotate (177Lu-octreotate), is effective not only in decreasing tumor size but also in reducing the severity of side effects that often accompany a cancer diagnosis.

22 Sep 2011

African Americans more likely than Caucasians to develop and die from lung cancer

Lung cancer, the leading cause of cancer death in the U.S., takes a particularly heavy toll on African Americans. Despite their lower smoking rates, African Americans are more likely than Caucasians to develop and die from lung cancer.

21 Sep 2011

UTHealth doctoral student receives ASM, NIH research fellowships for E. coli study

A doctoral student at The University of Texas Health Science Center at Houston (UTHealth) has been awarded two research fellowships to study the spread of E. coli, a hard-to-treat bacterium that can lead to food poisoning.

21 Sep 2011

ASU scientists receive USDA grants to combat food-related illness

Roughly 1 in six Americans are sickened every year by food-borne ailments, according to the Centers for Disease Control and Prevention. The effects of these illnesses range from acutely unpleasant to lethal, and the problem may be getting worse, as our food supply becomes more global, with an increasing number of antibiotic-resistant pathogens.

21 Sep 2011

Regulatory bias against taking oral anti-cancer medications with food places patients at risk of overdose

A regulatory bias against taking oral anti-cancer medications with food places many patients at increased risk for an overdose and forces them to "flush costly medicines down the toilet," argues Mark Ratain, MD, an authority on cancer-drug dosing.

20 Sep 2011

Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis

Santarus, Inc., a specialty biopharmaceutical company, today announced that analysis of top-line safety data from a double blind, multicenter 12-month extended use study in patients treated daily with either the investigational drug budesonide MMX 6 mg or placebo will be provided as support for the company's planned submission of a New Drug Application (NDA) for budesonide MMX 9 mg to the U.S. Food and Drug Administration (FDA) for the induction of remission of mild or moderate active ulcerative colitis.

20 Sep 2011

Report urges integrated aid approach to tackle poverty, disease

Action Against Hunger, Action for Global Health, End Water Poverty, PATH, Tearfund and WaterAid on Wednesday released a report that "provides clear and compelling evidence that a new combined approach to tackling poverty and disease that brings together work on water and sanitation, health, education and nutrition achieves better results for the world's poorest," according to a joint press release.

16 Sep 2011

ITA president hosts International Small Bowel Transplant Symposium

Fifty-two year-old Paul McNeel, a fire chief from Leonardtown, Maryland was 37 in 1996 when a sudden health problem caused the loss of his small intestine. Almost all of it had to be surgically removed to save his life. For 13 years after that, McNeel continued to fight fires and stayed alive only because he fed himself a special liquid formula through a tube that went from a port in his chest directly to his heart and into his bloodstream.

15 Sep 2011

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

Vertex Pharmaceuticals Incorporated today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK (telaprevir) tablets in people with genotype 1 chronic hepatitis C who were new to treatment.

15 Sep 2011

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Aeterna Zentaris Inc. earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer.

14 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking sales and marketing approval for vismodegib to treat people with advanced basal cell carcinoma (BCC), which includes metastatic and locally advanced BCC for whom surgery is inappropriate.

12 Sep 2011

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

12 Sep 2011

ASTMH annual meeting to explore latest research on infectious diseases

The 60th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) -- the largest of its kind in the world -- will bring together in one place global experts who are battling a wide range of bacteria, viruses, parasites and other pathogens that each year kill or sicken hundreds of millions of people.

12 Sep 2011

Gates Foundation's Ananya Alliance aims to improve newborn health in India

Usha Kiran Tarigopula, deputy director in global health at the Bill & Melinda Gates Foundation, writes about the Foundation's partnership with the state of Bihar, India through the Ananya Alliance "aimed at reducing maternal, newborn, and child mortality by 40 percent by 2015," in this "Inpatient Optimists" blog post, which is part of a series called "Global Conversations on Newborn Health in India."

12 Sep 2011

Diarrhea News and Research

Latest Diarrhea News and Research

2M Pakistanis affected by diseases related to widespread flooding in southern region

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Vaccinating infants against rotavirus decreases health care use and treatment costs

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Peptide receptor radiolabeled therapy shows promise against neuroendocrine tumors

African Americans more likely than Caucasians to develop and die from lung cancer

UTHealth doctoral student receives ASM, NIH research fellowships for E. coli study

ASU scientists receive USDA grants to combat food-related illness

Regulatory bias against taking oral anti-cancer medications with food places patients at risk of overdose

Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis

Report urges integrated aid approach to tackle poverty, disease

ITA president hosts International Small Bowel Transplant Symposium

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

ASTMH annual meeting to explore latest research on infectious diseases

Gates Foundation's Ananya Alliance aims to improve newborn health in India

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in